Zevra Therapeutics, Inc.ZVRA
What Zevra Therapeutics, Inc. does.
We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics. Our vision is realized through disciplined execution of our strategic plan and our core values — patient centricity, integrity, accountability, innovation, and courage — which guide our efforts to deliver long-term value. The commercialization of our lead product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and demonstrates our ability to advance therapies from development to market.
In February 2023, we changed our name to Zevra Therapeutics, Inc. Zevra, is the Greek word for zebra, which is the internationally recognized symbol for rare disease. This name reflects our intense focus and dedication to developing transformational, patient-focused therapies for rare diseases with limited or no treatment options available, or treatment areas with significant unmet needs.
Our strategic plan is focused on transforming Zevra into a leading rare-disease company. We are prioritizing the commercialization and global expansion of our lead product, MIPLYFFA, while OLPRUVA remains commercially available. We are also advancing the development of our clinical stage asset, celiprolol, and plan to further expand our pipeline through inorganic growth. We intend to become the preferred partner for assets that we believe will allow us to leverage the expertise and infrastructure that we have built to help mitigate risk and enhance our probability of success.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.3M | $28.6M | $10.2M | $27.5M | $23.6M | $106.5M |
| Net income | -$12.8M | -$8.6M | -$26.8M | -$46.0M | -$105.5M | $83.2M |
| Free cash flow | -$2.0M | $10.3M | -$18.8M | -$33.8M | -$69.7M | -$2.4M |
More on ZVRA.
- Zevra Therapeutics, Inc. summary
- Zevra Therapeutics, Inc. financial statements
- Zevra Therapeutics, Inc. key metrics
- Zevra Therapeutics, Inc. health scores and style box
- Zevra Therapeutics, Inc. earnings
- Zevra Therapeutics, Inc. dividends
- Zevra Therapeutics, Inc. valuation
- Zevra Therapeutics, Inc. ownership and insiders
- Zevra Therapeutics, Inc. peers
Figures from Zevra Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.